Home
Anticoagulant use has been critical for reducing the risk of stroke in patients with atrial fibrillation. However, currently available agents are often underutilized or utilized inappropriately primarily due to safety concerns, leading to suboptimal patient outcomes. Emerging evidence suggests that factor XI is a promising new target for inhibition of pathological thrombosis. Join us in this gameshow format and test your knowledge against your peers about thromboembolic disease and factor XI inhibition!